The market for the new, expensive biologic drugs created by living drugs may be normal. A team of researchers led by Molly Beinfeld, a public health researcher at Tufts Medical Center, has published evidence for that possibility in a new paper on what happens when "biosimilar," or competitors to biologics, show up.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.